Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma.

MLA

Chen, Anan, et al. “Atovaquone Enhances Antitumor Efficacy of TCR-T Therapy by Augmentation of ROS-Induced Ferroptosis in Hepatocellular Carcinoma.” Cancer Immunology, Immunotherapy, vol. 73, no. 3, Mar. 2024, pp. 1–15. EBSCOhost, https://doi.org/10.1007/s00262-024-03628-2.

APA

Chen, A., Yu, Z., Ma, N., Lu, X., Zhang, Y., Xu, W., Wang, Y., Xie, J., Qin, Y., Mo, G., Wu, S., Hou, J., & Zhu, W. (2024). Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 73(3), 1–15. https://doi.org/10.1007/s00262-024-03628-2

Chicago

Chen, Anan, Zhiwu Yu, Na Ma, Xinyu Lu, Yajing Zhang, Weikang Xu, Yiyue Wang, et al. 2024. “Atovaquone Enhances Antitumor Efficacy of TCR-T Therapy by Augmentation of ROS-Induced Ferroptosis in Hepatocellular Carcinoma.” Cancer Immunology, Immunotherapy 73 (3): 1–15. doi:10.1007/s00262-024-03628-2.